

Andrew L. Pecora, MD, F.A.C.P., C.P.E.
Chief Executive Officer,
Outcomes Matter Innovations
Professor of Medicine and Oncology,
Georgetown University School of Medicine
Associate Dean, Technology and Innovation,
School of Medicine at Seton Hall University
Board Member, CDI



A nationally recognized expert in care transformation, Andrew L. Pecora, MD, FACP, CPE, is at the forefront of the health-systems improvement movement. As Chief Executive Officer of Outcomes Matter Innovations (OMI), he is a national advocate for making medical practices more efficient and profitable, and at the same time, improving patient care. Dr Pecora, one of *Modern Healthcare's* 2019 "50 Most Influential Clinical Executives," is dedicated to pairing practices with artificial intelligence (AI) and health technologies to increase efficiencies, reduce costs and enable physicians to better do what they do best – heal patients.

Dr. Pecora came to OMI from Hackensack Meridian *Health*, where he was President, Physician Enterprise and Chief Innovation Officer. A certified hematologist and oncologist – and one of the world's leading experts in blood and marrow stem cell transplantation, cellular medicine and immunology research – Dr. Pecora played a pivotal role in the recruitment of leading oncologists, initiation of innovative research and clinical trials, expansion of patient care services and introduction of new, state-of-the-art technologies to shift administrative burdens from healthcare professionals.

While at Hackensack Meridian Health, he created and expanded the John Theurer Cancer Center, named one of the United States top 50 cancer centers – the only New Jersey institute with this designation – and played a key role in the success of multiple Hackensack Meridian strategic partnerships, including those with Memorial Sloan Kettering Cancer Center and Georgetown Lombardi Cancer Center.

Dr. Pecora was instrumental in the John Theurer Cancer Center approval from the National Cancer Institute as a research consortium member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center Consortium, awarded May 2019. This esteemed designation recognizes providers for their scientific leadership, community engagement, and the depth and breadth of their cancer research. The collaboration is one of just 16 NCI-designated cancer consortia.

Along with innovating in clinical settings, Dr. Pecora is a noted leader in building physician alliances. He was instrumental in the creation and development of Regional Cancer Care Associates (RCCA), one of the nation's largest oncology physician networks. Dr. Pecora is also executive chairman of COTA, a healthcare software analytics company guiding value-based care delivery for payers and providers. A medical innovator, he co-founded PCT Caladrius, LLC: a company focused on development, manufacturing and delivery of cell-based therapies, later sold to Hitachi.

Dr. Pecora has been awarded the prestigious BioNJ Dr. Sol J. Barer Award for vision, innovation and leadership; the ASCO Cancer Foundation Research Award and Gallo Award for outstanding cancer research; tapped as one of America's Top Doctors, listed as a "Who's Who in the World;"; and selected as the *PM360* Uber ELITE honoree. His award-winning research has been published in numerous peer-review medical journals and funded by organizations including the National Cancer Institute, AHEPA Research Foundation and biopharma giants Amgen and Merck.

Dr. Pecora is a Professor of Medicine and Oncology at Georgetown University and University of Medicine and Dentistry of New Jersey. He is Associate Dean for Technology and Innovation at Hackensack Meridian School of Medicine at Seton Hall University. He received his medical degree from the University of Medicine and Dentistry of New Jersey and completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center.